Reveal Spatial Biomarkers With Multiplexed Imaging Mass Cytometry
Whitepaper
Published: November 14, 2024
Credit: Standard Biotools
To interpret neural disease origin, progression, prognosis and treatment options, it is essential to understand the cellular and spatial composition of neural tissues.
Imaging mass cytometry (IMC) overcomes the limitations of traditional cyclic fluorescent methods to uncover the spatial distribution of over 40 distinct protein markers simultaneously, without interference from the tissue degradation and autofluorescence artifacts usually found in brain tissue.
This whitepaper explores the translational and clinical applications of IMC to develop biomarkers and future treatment strategies in neuro-oncology and neurodegenerative studies.
Download this whitepaper to discover how to:
Detect surface and intracellular targets without autofluorescence interference Resolve neural and non-neural cell distribution on the same tissue section Reveal key biological insights within spatial context to develop diagnostics and therapeutics
IMAGE LOOKBOOK
NEUROSCIENCE
Revealing Spatial Biomarkers in
Neural Tissues with Multiplexed
Imaging Mass Cytometry Technology
Explore new views of cellular and structural composition of neural tissues
to unlock new understanding of spatial biology in clinical applications
Introduction
Understanding the cellular and spatial composition of tissues is crucial for interpreting neural
disease origin, progression, prognosis and treatment options. Imaging Mass Cytometry™ (IMC™) is a
spatial biology technology that can uncover novel phenotypes and identify therapeutic targets that
may be relevant to developing biomarkers and future treatment strategies in neuro-oncology and
neurodegenerative studies.
KEY TAKEAWAYS
• Using a combination of imaging modes and ready-to-go high-plex panels on
the same tissue section provides researchers with more flexibility to resolve the
distribution of neural and non-neural cell lineages.
• Rapid imaging modes reveal key biological insights within spatial context that
are relevant for developing potential diagnostic and therapeutic applications.
Preview Mode
Number of markers: 42
Acquisition time: 20 minutes
Sample: normal mouse brain
(13 mm x 15 mm)
Cell Mode
Number of markers: 42
Acquisition time: 2 hours
Sample: normal mouse brain
(2 mm x 2 mm)
Resolution: 1 μm
Tissue Mode
Number of markers: 42
Acquisition time:
5 hours and 50 minutes
Sample: mouse glioblastoma
brain (24 mm x 16 mm)
Resolution: 5 μm
Imaging Mass Cytometry
technology enables highly
specific detection of surface
and intracellular targets
without interference from
autofluorescent tissues.
Ready-to-use
panels
Fast high-parameter panel
design by combining
pre-optimized panels with
other relevant IMC panels.
NEURO-ONCOLOGY
PARKINSON’S DISEASE
ALZHEIMER’S DISEASE
MULTIPLE SCLEROSIS
PROTEINOPATHIES
SYNTAU MIXED
PATHOLOGY
2 mm
Unlike traditional cyclic fluorescent methods, IMC
technology can uncover the spatial distribution of 40-plus
distinct protein markers simultaneously without tissue
degradation and autofluorescence artifacts usually
observed in brain tissue. This lookbook showcases
translational and clinical applications of multiplexed tissue
analysis using IMC technology.
Preview Mode scan rapidly identified areas with high tumor and immune cell activity, which was used to identify relevant regions of interest for detailed Cell
Mode investigation. Multiplex Cell Mode images using tumor- (top) and immune- (bottom) specific markers demonstrate the heterogeneity of the TME.
Pixel-clustering analysis reveals highly specialized tumor, immune and stromal tissue compartments
Tissue Mode imaging demonstrates the tumor and immune cell heterogeneity of mouse glioblastoma tissue. Metabolically active tumor cells were
detected at the periphery of tumor. Vascularization was observed across the tumor in non-necrotic areas. Immune cells were detected in high
concentration at the tumor margin and in necrotic cores. Unsupervised pixel-clustering analysis with hierarchical clustering quantitatively segregates
highly specialized subcompartments and detects areas containing subsets of differentiated tumor cells, immune hot and cold areas, stromal
compartments, vasculature and extracellular matrix.
Neuro-Oncology
In a study of mouse embryo, normal brain and glioblastoma (GBM) tissue, a 43-marker
neuro-oncology panel composed of the Maxpar™ OnDemand Mouse Immuno-Oncology
IMC Panel Kit and the Maxpar Neuro Phenotyping IMC Panel Kit revealed the spatial
distribution of over 40 distinct molecular markers.
Mouse neuro-oncology panel detects tumor cell and immune cell infiltration in glioblastoma
View the
study details
2 mm
2 mm
2 mm
2 mm
200 μm
200 μm
2 mm
2 mm
2 mm
Preview Mode scan rapidly
identified spatial positioning of
brain-specific compartments.
In the cerebellum, tissue
morphology with specific
cellular compartments such as
the cortex, individual lobules
and neuronal cell bodies is
visualized. The hippocampus
demonstrates structured
spatial cellular distribution.
In the olfactory bulb, various
cell populations including
oligodendrocytes, neurons,
metabolically active cells and
vasculature are highlighted.
Quantitative assessment of specific tissue compartments in the developing mouse embryo
Tissue Mode imaging was
performed in hours to
assess whole mouse E18.5
embryo tissue structure and
composition. Expression of
neuronal specific markers was
observed in the developing
brain and spinal column.
Organ-specific tissue
compartments were also
highlighted. Unsupervised
pixel-clustering analysis
along with hierarchical
clustering quantitatively
segregates highly specialized
subcompartments in the
developing mouse embryo.
Generating spatial maps of specialized tissue substructures in the mouse brain
A 40-marker panel was designed to study the TME of mouse neurological tissues.
Maxpar OnDemand Mouse Neuro-Oncology IMC Bundle (PN 9100005NO) Maxpar IMC Cell
Segmentation Kit
PN 201500 Maxpar OnDemand
Mouse Tissue
Architecture IMC
Panel Kit
PN 9100001
Maxpar OnDemand
Mouse Cancer Cell
Process IMC
Panel Kit
PN 9100002
Maxpar OnDemand
Mouse Immune
Phenotyping IMC
Panel Kit
PN 9100003
Maxpar OnDemand
Mouse Immune
Activation IMC
Panel Kit
PN 9100004
Maxpar Neuro
Phenotyping IMC
Panel Kit
PN 201337
1.5 mm
200 µm
1.5 mm
1.5 mm 1.5 mm
200 µm 200 µm
2 mm
Olfactory bulb
Fast screening of the entire slide combined with single-cell analysis
Applying three rapid imaging modes to a tissue microarray (TMA) containing dozens of human
glioma cores identified the spatial distribution of over 40 distinct molecular markers.
View the
study details
Preview Mode Cell Mode
Preview Mode was applied to rapidly screen tumor cores for expression signatures associated with tumor immuno-oncology processes. This enabled
biomarker-guided selection of areas in tumor tissue that were imaged at higher resolution and analyzed with single-cell analysis using Cell Mode.
Tissue Mode facilitates identification of prominent features in all TMA cores
Tissue Mode
From larger samples to TMA cores, Tissue Mode generates a high-quality scan of the entire tissue section in a matter of hours with higher spot-size
ablations enabling entire tissue analysis using pixel-clustering methods. This is an especially high-throughput modality with TMAs, as 18 2 mm TMA
cores can be imaged in 1 hour and 35 minutes. In the figure above, Tissue Mode visualizes tissue compartments and indicates high heterogeneity of
human glioma cores. Cores of interest are selected for subsequent pixel-clustering analysis.
18 2 mm TMA cores can be imaged
in 1 hour and 35 minutes
Preview Mode in combination with neurodegenerative panels allow whole tissue visualization of the main protein contributors to disease pathology:
amyloid precursor protein (APP) in amyloid plaques and Tau in tangles of AD (left panel); p-αSynuclein (p-αSyn) in Lewy bodies and Lewy neurites of PD
(middle panel); and large areas of lost myelin in a lesion of MS (right panel).
Revealing heterogeneity of protein distribution at subcellular resolution
Data from Cell Mode acquisition was used to conduct single-cell analysis. Locations of the same aggregates with the most abundant presence of APP
and pTau, Lewy bodies and area of demyelination are marked with arrowheads in a Cell Mode image.
Neurodegenerative Disease
In this application, diseased brain tissues samples were stained with modular
subpanels including one of three neurodegenerative subpanels, each specific
to a disease type: Parkinson’s disease (PD), Alzheimer’s disease (AD) or multiple
sclerosis (MS).
Identifying regions of main protein contributors to disease pathology
View the
study details
2 mm
Detection of pathological tissue compartments in the neurodegenerative brain
Tissue Mode in combination
with neurodegenerative
panels allows whole tissue
visualization of the main
protein contributors to
disease pathology: amyloid
precursor protein (APP) in
amyloid plaques and Tau in
tangles of AD (left panel);
p-αSynuclein (p-αSyn) in Lewy
bodies and Lewy neurites of
PD (middle panel); and large
areas of lost myelin in a lesion
of MS (right panel).
Pixel-clustering analysis reveals extracellular aggregates and distinct morphology clusters
A 41-marker panel, comprised of disease-specific neurodegenerative subpanels, was designed to study diseased
brain tissue.
Human Immuno-Oncology IMC Panel, 3 1 Antibodies (PN 201509)
Cell Functional
State
PN 201514
Stromal
Cell
PN 201511
Basic
Immune
PN 201518
Lymphoid
PN 201512
Myeloid
PN 201513
Basic Tissue
Architecture
PN 201517
Maxpar Neuro
Phenotyping
7 Antibodies
PN 201337
Parkinson’s
Disease
PN 9100006
Maxpar
IMC Cell
Segmentation Kit
PN 201500
Alzheimer’s
Disease
PN 9100007
Multiple Sclerosis
PN 9100008
In AD, pixel-clustering analysis unveiled eight distinct
morphology clusters, such as gray matter-associated
and white matter-associated microglia (combined in one
cluster); three distinct populations of neurons, fibrous
and protoplasmic astrocytes (combined in one cluster);
oligodendrocytes; and vasculature, alongside the
identification of two functional amyloid aggregate clusters.
The arrangement of APP and Tau hints at a potential
aggregate stabilization and overall synergy among
those proteins, alongside αSyn, all known to be prone to
misfolding in the diseased brain.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: www.standardbio.com/legal/salesterms. Patent and License Information:
www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole
property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
FLDM-01382 Rev 01
Learn more at
standardbio.com/neuroscience
Protocol
Section tissue or
tissue microarray
onto a slide.
Stain tissue with
one antibody
cocktail.
Image tissue with
Hyperion™ XTi
Imaging System.
Collect highdimensional data.
Perform data
analysis.
• Single-cell analysis
• Pixel-clustering
analysis
Ordering information for referenced panels
Product Part Number
Human Immuno-Oncology IMC Panel,
31 Antibodies
201509
Maxpar Neuro Phenotyping IMC Panel Kit 201337
Maxpar OnDemand Mouse Neuro-Oncology
IMC Bundle
9100005NO
Parkinson’s Disease IMC Panel, 3 Antibodies 9100006
Alzheimer’s Disease IMC Panel, 3 Antibodies 9100007
Multiple Sclerosis IMC Panel, 3 Antibodies 9100008
Maxpar IMC Cell Segmentation Kit 201500
Cell-ID™ Intercalator-Ir 201192B
SBI Services Lab
References
Raza, Q. et al. “Novel whole slide imaging modes for Imaging Mass
Cytometry reveal cellular and structural composition of mouse
glioblastoma.” Cancer Research 84 (2024): 1,450–1,450.
Raza, Q. et al. “Next generation of spatial biology: high-throughput
multiplexed Imaging Mass Cytometry with whole slide modes.” Cancer
Research 84 (2024): 3,800–3,800.
Inquire about our in-house service lab that can run
samples for you. Simply ship your samples and get
results within 72 hours of sample receipt.
Zabinyakov, N. et al. “Novel whole slide imaging modes for Imaging
Mass Cytometry unveil extensive cellular heterogeneity in human
gliomas.” Cancer Research 84 (2024): 5,501–5,501.
Zabinyakov, N. et al. “Imaging Mass Cytometry spatially resolves
immune activity in neurodegenerative brain pathology.” Journal for
Neuroscience (2024).